Becton Dickinson & Co (NYSE: BDX)

$147.63 ▲ +1.03 (+0.70%)

As of May 22, 2026 04:00 PM

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0000010795

Market Cap 41.51 Bn

P/E 29.74

P/S 1.94

Div. Yield 0.03

ROIC (Qtr) 0.00

Total Debt (Qtr) 17.28 Bn

Revenue Growth (1y) (Qtr) 5.22

Add ratio to table...

About

Becton Dickinson and Company is a global medical technology company engaged in the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. The company serves healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. BD provides customer solutions focused on improving medication management and patient safety, supporting infection prevention practices, equipping surgical and interventional procedures,...

Becton Dickinson and Company is a global medical technology company engaged in the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. The company serves healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. BD provides customer solutions focused on improving medication management and patient safety, supporting infection prevention practices, equipping surgical and interventional procedures, improving drug delivery, aiding anesthesiology care, enhancing the diagnosis of infectious diseases and cancers, and advancing cellular research and applications.

BD generates revenue through the sale of its medical technologies and devices across multiple product lines. The company earns income from medication delivery solutions such as peripheral intravenous catheters, central lines, vascular access technology, and needle-free IV connectors. Revenue is also derived from medication management solutions including infusion pumps, automated medication dispensing systems, and pharmacy automation systems. Additional revenue streams come from pharmaceutical systems like prefillable drug delivery systems, advanced patient monitoring systems, diagnostic solutions for infectious diseases and cancers, biosciences research tools, specimen management products, and interventional specialty products for vascular, urology, oncology, and surgical applications.

The company operates through the following segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences.

• Medical Essentials produces a broad array of medical technologies and devices used to improve healthcare delivery in various settings, including peripheral intravenous catheters, advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care products, vascular preparation items, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detection systems, conventional and safety hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems.

• Connected Care includes IV medication safety and infusion therapy delivery systems such as infusion pumps, dedicated disposables, and IV fluids; medication compounding workflow systems; automated medication dispensing; automated supply management systems; medication inventory optimization and tracking systems; informatics and analytics solutions for enterprise medication management; and pharmacy automation systems.

• BioPharma Systems provides prefillable drug delivery systems—prefillable syringes, safety, shielding, and self-injection systems and support services—to pharmaceutical companies for use as containers for injectable pharmaceutical products, which are then placed on the market as drug/device combinations.

• Interventional provides vascular, urology, oncology, and surgical specialty products intended for single use or temporary or permanent implantation, including hernia and soft tissue repair products, biological and bioresorbable grafts, biosurgery products, BD Surgiphor™ Antimicrobial Irrigation System, BD ChloraPrep™ surgical infection prevention products, percutaneous transluminal angioplasty balloon catheters, radio frequency ablation catheters, peripheral vascular stents, self-expanding and balloon-expandable stent grafts, vascular grafts, drug coated balloons, ports, biopsy devices, chronic dialysis equipment, inferior vena cava filters, endovascular fistula creation devices, drainage products, atherectomy and thrombectomy systems, urine management and measurement devices, indwelling, intermittent and external urine catheters, kidney stone management devices, targeted temperature management systems, and fecal management devices.

• Life Sciences provides products for the safe collection and transport of diagnostic specimens, instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers, and research and clinical tools that facilitate the study of cells and cellular components to aid in drug and vaccine development and disease diagnosis and management, including automated blood culturing and tuberculosis culturing systems, microorganism identification and drug susceptibility systems, microbiology laboratory automation and informatics, dehydrated, liquid, and plated media for clinical and industrial microbiology applications, molecular testing systems for infectious diseases and women’s health, rapid diagnostic assays for point-of-care respiratory infection testing, fluorescence-activated cell sorters and analyzers, antibodies and kits for cell analysis, reagents for life science research, solutions for high-throughput single-cell gene and protein expression analysis, and clinical oncology, immunological (HIV), and transplantation diagnostic/monitoring reagents, analyzers, and informatics.

BD operates in the increasingly complex and challenging medical technology marketplace, competing with companies of varying sizes that have greater financial resources or specialization in niche markets such as molecular diagnostics, non-traditional point of care, at-home testing, safety-engineered devices, and life sciences. The company maintains its competitive position through investments in research and development, quality management, product innovation, manufacturing, and supply chain improvements, leveraging factors such as price, quality, innovation, service, reputation, distribution, and promotion to differentiate its offerings.

BD serves hospitals and clinics, physician office practices, consumers and retail pharmacies, governmental and nonprofit public health agencies, pharmaceutical companies, healthcare workers, hospitals, laboratories and clinics, blood banks, academic and government institutions, pharmaceutical and biotechnology companies, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business.

Investment thesis

Bull case

The transition from a diversified medical device and life‑sciences conglomerate to a focused, high‑margin medtech platform creates a clear strategic narrative that the market is underestimating. The divestiture of the biosciences and diagnostics units, coupled with the $4 billion cash distribution, provides immediate liquidity and a disciplined capital allocation framework that prioritizes share repurchases and debt reduction. By shedding lower‑margin, high‑growth segments that required significant investment to scale, the company is now positioned to concentrate resources on its “fast‑growth, high‑margin” portfolio, which already includes AI‑driven connected care, pharmacy automation, biologics delivery and advanced tissue regeneration. This focus is expected to lift operating margins, improve free cash flow and enhance the ability to fund an accelerated product pipeline without diluting equity.
The Q1 earnings demonstrated robust operational execution, with a 53.4 % adjusted gross margin and a 21.2 % operating margin despite a 140‑basis‑point margin compression from tariffs. The company’s ability to offset tariff hits with productivity gains—an 8 % quarterly improvement—shows an effective lean manufacturing strategy that has already reduced the global plant network by roughly half. Such efficiencies increase resilience to supply‑chain shocks and provide a cost advantage in a market increasingly sensitive to price competition. When combined with a strong free‑cash‑flow conversion of 66 %, the company can sustain high-quality capital returns and potentially accelerate R&D or opportunistic M&A.
The innovation pipeline is a hidden catalyst that management has only lightly highlighted, yet it underpins several high‑impact product launches within the next 12–18 months. New devices such as Avatene Flowable, SurgiFor, HemoSphere Stream and the upcoming SurgiFore Pulse target emerging markets—biosurgery, wound irrigation and advanced hemostasis—each worth hundreds of millions in untapped revenue potential. These launches are supported by an accelerated development timeline, with some projects achieving 6‑12 month time‑to‑market reductions through targeted R&D Kaizens. When fully commercialized, these products will diversify revenue streams beyond consumables, improving the company’s risk profile against a single‑segment downturn.
Connected care and pharmacy automation are high‑margin growth engines that are already showing double‑digit revenue expansion, with APM and pharmacy automation each achieving high single‑digit and double‑digit growth, respectively. The company’s strategic investments—$30 million in incremental sales efforts and expanded sales forces in APM, PI, and VDB—signal a concerted push to capture additional market share in these mature yet evolving categories. These efforts are supported by a robust data ecosystem that ties device usage to clinical outcomes, thereby justifying price premiums and strengthening customer lock‑in. The momentum in these segments provides a structural growth path that is likely to accelerate as the shift toward outpatient and home‑based care continues.
Biologics delivery remains a core strength that is well positioned to benefit from the rising prevalence of chronic disease and the growing pipeline of GLP‑1 therapeutics. The company’s portfolio now includes more than 80 novel and biosimilar GLP‑1 molecules contracted, giving it a broad geographic reach that spans the U.S., China, Europe, Latin America and Southeast Asia. Even as vaccine demand tapers, biologics will continue to grow, providing a reliable source of recurring consumables revenue. Coupled with the fact that GLP‑1 device sales are driven by high‑margin prescriptions, this segment represents a scalable, long‑term growth engine that will likely outpace other traditional medical device categories.

The transition from a diversified medical device and life‑sciences conglomerate to a focused, high‑margin medtech platform creates a clear strategic narrative that the market is underestimating. The divestiture of the biosciences and diagnostics units, coupled with the $4 billion cash distribution, provides immediate liquidity and a disciplined capital allocation framework that prioritizes share repurchases and debt reduction. By shedding lower‑margin, high‑growth segments that required significant investment to scale, the company is now positioned to concentrate resources on its “fast‑growth, high‑margin” portfolio, which already includes AI‑driven connected care, pharmacy automation, biologics delivery and advanced tissue regeneration. This focus is expected to lift operating margins, improve free cash flow and enhance the ability to fund an accelerated product pipeline without diluting equity.
The Q1 earnings demonstrated robust operational execution, with a 53.4 % adjusted gross margin and a 21.2 % operating margin despite a 140‑basis‑point margin compression from tariffs. The company’s ability to offset tariff hits with productivity gains—an 8 % quarterly improvement—shows an effective lean manufacturing strategy that has already reduced the global plant network by roughly half. Such efficiencies increase resilience to supply‑chain shocks and provide a cost advantage in a market increasingly sensitive to price competition. When combined with a strong free‑cash‑flow conversion of 66 %, the company can sustain high-quality capital returns and potentially accelerate R&D or opportunistic M&A.
The innovation pipeline is a hidden catalyst that management has only lightly highlighted, yet it underpins several high‑impact product launches within the next 12–18 months. New devices such as Avatene Flowable, SurgiFor, HemoSphere Stream and the upcoming SurgiFore Pulse target emerging markets—biosurgery, wound irrigation and advanced hemostasis—each worth hundreds of millions in untapped revenue potential. These launches are supported by an accelerated development timeline, with some projects achieving 6‑12 month time‑to‑market reductions through targeted R&D Kaizens. When fully commercialized, these products will diversify revenue streams beyond consumables, improving the company’s risk profile against a single‑segment downturn.
Connected care and pharmacy automation are high‑margin growth engines that are already showing double‑digit revenue expansion, with APM and pharmacy automation each achieving high single‑digit and double‑digit growth, respectively. The company’s strategic investments—$30 million in incremental sales efforts and expanded sales forces in APM, PI, and VDB—signal a concerted push to capture additional market share in these mature yet evolving categories. These efforts are supported by a robust data ecosystem that ties device usage to clinical outcomes, thereby justifying price premiums and strengthening customer lock‑in. The momentum in these segments provides a structural growth path that is likely to accelerate as the shift toward outpatient and home‑based care continues.
Biologics delivery remains a core strength that is well positioned to benefit from the rising prevalence of chronic disease and the growing pipeline of GLP‑1 therapeutics. The company’s portfolio now includes more than 80 novel and biosimilar GLP‑1 molecules contracted, giving it a broad geographic reach that spans the U.S., China, Europe, Latin America and Southeast Asia. Even as vaccine demand tapers, biologics will continue to grow, providing a reliable source of recurring consumables revenue. Coupled with the fact that GLP‑1 device sales are driven by high‑margin prescriptions, this segment represents a scalable, long‑term growth engine that will likely outpace other traditional medical device categories.

Bear case

The company’s earnings guidance has been cut by roughly 20 % from previous forecasts, largely due to ongoing headwinds in vaccines, China, and the Alaris infusion pump line. This downward revision reflects the reality that the company still faces significant cost pressures—tariffs, global supply‑chain constraints, and intense price competition— that erode gross and operating margins. While the company has managed to offset some of these impacts through productivity gains, the guidance signals a potential long‑term contraction in earnings growth that could pressure share price in the medium term. Investors should be wary of the cumulative effect of these headwinds, which may outweigh the upside from new product launches if the company cannot maintain the same margin trajectory.
The China market remains a significant source of volatility, with a 10 % portfolio of Alaris vaccines subject to a price‑based procurement (VBP) program that has not yet fully abated. Even though the company expects 80 % of its China portfolio to transition to VBP by fiscal 2026, the current price compression is eroding revenue and margin growth in a key growth region. The uncertainty around the timing of tariff reductions and the potential for further supply‑chain disruptions could exacerbate the headwind. As China accounts for a sizable share of overall revenue, any prolonged downturn in that market could create a cyclical drag that is difficult to mitigate with the company’s current strategy.
Alaris, despite approaching a 60 % market share, continues to experience declining growth due to an extensive multi‑year upgrade wave that was undertaken to remediate past product quality issues. The company’s remediation efforts have temporarily strained resources and diluted short‑term profitability. Even with a 100‑basis‑point share gain in the first quarter, the company’s revenue growth in the Alaris segment is still lagging, and the company has to sustain significant commercial investment to maintain its competitive position. As the company continues to compete in a market with strong incumbents and rapidly advancing technologies, any failure to sustain growth in this segment could pose a material risk to the company’s top line.
The heavy reliance on recurring consumables revenue—over 90 % of total revenue—poses a structural risk, as the consumable business is vulnerable to cost‑controlling initiatives from payers, insurers, and hospitals. While recurring revenue offers stability, it also makes the company sensitive to payer reforms and shifts toward bundled payment models that could compress margins. In addition, as competitors launch lower‑cost or more technologically advanced alternatives, the company may face pricing pressure that erodes its high‑margin profile. The lack of diversification into non‑recurring, high‑margin services or software solutions could limit the company’s ability to offset consumables volatility.
The company’s ambitious “tuck‑in” M&A strategy—while providing incremental growth—introduces integration risk and potential dilution of operating focus. The recent $4 billion transaction with Waters, while strategically clean, required a complex reverse Morris Trust structure that could strain management bandwidth. Future tuck‑ins, especially those that are opportunistic rather than synergistic, risk failing to deliver the projected accretive returns on revenue and EPS. Moreover, the company’s stated commitment to non‑dilutive M&A may limit its ability to pursue larger, transformational deals that could be necessary to keep pace with disruptive competitors.

The company’s earnings guidance has been cut by roughly 20 % from previous forecasts, largely due to ongoing headwinds in vaccines, China, and the Alaris infusion pump line. This downward revision reflects the reality that the company still faces significant cost pressures—tariffs, global supply‑chain constraints, and intense price competition— that erode gross and operating margins. While the company has managed to offset some of these impacts through productivity gains, the guidance signals a potential long‑term contraction in earnings growth that could pressure share price in the medium term. Investors should be wary of the cumulative effect of these headwinds, which may outweigh the upside from new product launches if the company cannot maintain the same margin trajectory.
The China market remains a significant source of volatility, with a 10 % portfolio of Alaris vaccines subject to a price‑based procurement (VBP) program that has not yet fully abated. Even though the company expects 80 % of its China portfolio to transition to VBP by fiscal 2026, the current price compression is eroding revenue and margin growth in a key growth region. The uncertainty around the timing of tariff reductions and the potential for further supply‑chain disruptions could exacerbate the headwind. As China accounts for a sizable share of overall revenue, any prolonged downturn in that market could create a cyclical drag that is difficult to mitigate with the company’s current strategy.
Alaris, despite approaching a 60 % market share, continues to experience declining growth due to an extensive multi‑year upgrade wave that was undertaken to remediate past product quality issues. The company’s remediation efforts have temporarily strained resources and diluted short‑term profitability. Even with a 100‑basis‑point share gain in the first quarter, the company’s revenue growth in the Alaris segment is still lagging, and the company has to sustain significant commercial investment to maintain its competitive position. As the company continues to compete in a market with strong incumbents and rapidly advancing technologies, any failure to sustain growth in this segment could pose a material risk to the company’s top line.
The heavy reliance on recurring consumables revenue—over 90 % of total revenue—poses a structural risk, as the consumable business is vulnerable to cost‑controlling initiatives from payers, insurers, and hospitals. While recurring revenue offers stability, it also makes the company sensitive to payer reforms and shifts toward bundled payment models that could compress margins. In addition, as competitors launch lower‑cost or more technologically advanced alternatives, the company may face pricing pressure that erodes its high‑margin profile. The lack of diversification into non‑recurring, high‑margin services or software solutions could limit the company’s ability to offset consumables volatility.
The company’s ambitious “tuck‑in” M&A strategy—while providing incremental growth—introduces integration risk and potential dilution of operating focus. The recent $4 billion transaction with Waters, while strategically clean, required a complex reverse Morris Trust structure that could strain management bandwidth. Future tuck‑ins, especially those that are opportunistic rather than synergistic, risk failing to deliver the projected accretive returns on revenue and EPS. Moreover, the company’s stated commitment to non‑dilutive M&A may limit its ability to pursue larger, transformational deals that could be necessary to keep pace with disruptive competitors.

Consolidation Items Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ISRG	Intuitive Surgical Inc	156.17 Bn	52.64	14.76	-
2	BDX	Becton Dickinson & Co	41.51 Bn	29.74	1.94	17.28 Bn
3	RMD	Resmed Inc	30.43 Bn	20.13	5.50	0.26 Bn
4	WST	West Pharmaceutical Services Inc	22.78 Bn	42.07	7.07	0.20 Bn
5	SOLV	Solventum Corp	13.39 Bn	9.37	1.62	5.08 Bn
6	COO	Cooper Companies, Inc.	12.33 Bn	31.01	2.97	2.50 Bn
7	ALGN	Align Technology Inc	11.65 Bn	27.31	2.84	-
8	BAX	Baxter International Inc	9.81 Bn	-72.70	0.91	9.46 Bn

Research Tools

Developers

Becton Dickinson & Co (NYSE: BDX)

About

Investment thesis

Bull case

Bear case

Consolidation Items Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

Becton Dickinson & Co (NYSE: BDX)

About

Investment thesis

Bull case

Bear case

Consolidation Items Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password